Karyopharm Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Karyopharm Therapeutics Inc. (KPTI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are KPTI insiders buying or selling?
In the last 12 months, Karyopharm Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($220.3K) — net selling of $220.3K. Since January 2018, Trabud has recorded 260 Form 4 filings for KPTI: 4 buys ($390.3K) and 256 sells ($58.2M).
Source: SEC EDGAR Form 4
What stands out
- No Karyopharm Therapeutics Inc. insider made an open-market purchase in the last 12 months; the 16 reported open-market sales totaled $220.3K.
Key Statistics (January 2018 – Oct 2, 2026)
Total Form 4 filings
260
SEC EDGAR
Insider filers
20
Insider buys (4)
$390.3K
Insider sells (256)
$58.2M
Insider sentiment
Net sellingNet insider flow of $57.8M in net selling since January 2018, and $220.3K in net selling over the last 12 months.
Recent KPTI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 378 | $1.19 | $449.82 | SEC ↗ |
| Sep 2, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 19 | $2.02 | $38.38 | SEC ↗ |
| Jul 30, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 189 | $7.10 | $1.3K | SEC ↗ |
| May 15, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 403 | $9.50 | $3.8K | SEC ↗ |
| May 15, 2026 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 408 | $9.50 | $3.9K | SEC ↗ |
| May 15, 2026 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sale | 324 | $9.50 | $3.1K | SEC ↗ |
| May 15, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 53 | $9.50 | $503.5 | SEC ↗ |
| May 15, 2026 | Richard A. Paulson | President and CEO | Sale | 2.2K | $9.50 | $20.9K | SEC ↗ |
| May 15, 2026 | Michael Mano | EVP, CLO&Secretary | Sale | 266 | $9.50 | $2.5K | SEC ↗ |
| Apr 22, 2026 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 449 | $8.94 | $4.0K | SEC ↗ |
| Mar 3, 2026 | Richard A. Paulson | President and CEO | Sale | 12.4K | $9.41 | $116.3K | SEC ↗ |
| Mar 3, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 5.1K | $9.41 | $48.0K | SEC ↗ |
| Feb 19, 2026 | Stuart Poulton | EVP, Chief Development Officer | Sale | 378 | $8.63 | $3.3K | SEC ↗ |
| Feb 4, 2026 | Lori Macomber | EVP, CFO & Treasurer | Sale | 1.6K | $6.30 | $10.2K | SEC ↗ |
| Jan 29, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 50 | $7.03 | $351.5 | SEC ↗ |
| Jan 22, 2026 | Kristin Abate | Chief Accounting Officer | Sale | 265 | $5.96 | $1.6K | SEC ↗ |
| Oct 3, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 362 | $6.30 | $2.3K | SEC ↗ |
| Sep 16, 2025 | Richard A. Paulson | President and CEO | Sale | 1.3K | $6.43 | $8.1K | SEC ↗ |
| Sep 16, 2025 | Michael Mano | SVP, General Counsel&Secretary | Sale | 234 | $6.43 | $1.5K | SEC ↗ |
| Sep 16, 2025 | Stuart Poulton | EVP, Chief Development Officer | Sale | 401 | $6.43 | $2.6K | SEC ↗ |
| Sep 16, 2025 | Reshma Rangwala | EVP & Chief Medical Officer | Sale | 408 | $6.43 | $2.6K | SEC ↗ |
| Sep 16, 2025 | Sohanya Roshan Cheng | EVP & Chief Commercial Officer | Sale | 325 | $6.43 | $2.1K | SEC ↗ |
| Sep 16, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 23 | $6.43 | $147.89 | SEC ↗ |
| Sep 4, 2025 | Kristin Abate | Chief Accounting Officer | Sale | 12 | $6.78 | $81.36 | SEC ↗ |
| Jul 30, 2025 | Stuart Poulton | EVP, Chief Development Officer | Sale | 191 | $4.37 | $834.67 | SEC ↗ |
Showing the 25 most recent of 260 Form 4 filings for Karyopharm Therapeutics Inc..
Most active KPTI insiders
- Michael Kauffman49 filings
- Sharon Shacham49 filings
- Richard A. Paulson41 filings
- Christopher Brett Primiano14 filings
- Mansoor Raza Mirza14 filings
Ask anything about KPTI insider activity
Use Trabud's AI agent to query Karyopharm Therapeutics Inc.'s Form 4 history in plain English — "Show me KPTI CEO purchases this year" or compare it against any other ticker.
Open the AI agentKPTI insider trading FAQ
Are Karyopharm Therapeutics Inc. insiders buying or selling?
In the last 12 months, Karyopharm Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 16 sales ($220.3K) — net selling of $220.3K. Since January 2018, Trabud has recorded 260 Form 4 filings for KPTI: 4 buys ($390.3K) and 256 sells ($58.2M). Over the full record that is net selling of $57.8M.
How many insiders trade KPTI stock?
20 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Karyopharm Therapeutics Inc.. The most recent filing was accepted on Oct 2, 2026.
Where does Trabud get KPTI insider trading data?
All KPTI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.